Introduction {#S0001}
============

By the end of the twentieth century, two decades after the HIV epidemic became visible, substantial success in slowing down HIV transmission had been achieved with ongoing prevention strategies, but it seemed far from stopping epidemic growth \[[@CIT0001], [@CIT0002]\]. Conversely, the use of combined antiretroviral treatment (ART) to prevent disease progression \[[@CIT0003]\] and the development of effective regimes to prevent mother-to-child transmission (PMTCT) \[[@CIT0004]\] were major steps in the HIV response.

As a corollary to "highly active antiretroviral treatment," people discussed the possibility of "highly active prevention" \[[@CIT0005]\]. The development of effective antiretrovirals (ARVs) led, from the start, to conceiving of biomedical prevention tools to decrease either susceptibility in uninfected people or infectiousness among people living with HIV (PLH). Given the lack of an effective HIV vaccine, key trials addressed several testable strategies that applied biomedical principles to HIV prevention, including sexually transmitted infection (STI) control, male medical circumcision, and the oral or topical use of ARV drugs to reduce susceptibility among the uninfected \[[@CIT0006]--[@CIT0014]\], as well as earlier ART initiation among positives to reduce infectivity \[[@CIT0015]\]. Over a decade later, several new prevention strategies have been proven efficacious, and others are very promising \[[@CIT0016], [@CIT0017]\]. Among newly available technologies, evidence of real-life effectiveness is quickly accumulating for oral PrEP.

Simultaneously, in line with the WHO Social Determinants of Health approach \[[@CIT0018]\], HIV risk is now understood as resulting from individual, interpersonal, community-level, and social-structural factors \[[@CIT0019], [@CIT0020]\]. In response to those, "structural interventions" targeting legal, institutional, social, cultural, and economic determinants of HIV vulnerability are considered essential to the HIV response \[[@CIT0021]\].

This new environment of bio-behavioural, individual-level interventions, along with appropriate social-structural strategies, is consolidating a framework for combination prevention \[[@CIT0022]--[@CIT0024]\]. In this paper, we focus on the origin, present status, and potential contribution of PrEP within the combination HIV prevention framework.

Discussion {#S0002}
==========

Pharmacologic prophylaxis in public health and the concept of HIV PrEP {#S0002-S20001}
----------------------------------------------------------------------

Over the past few decades, the use of specific medications to prevent clinical conditions has become standard practice in preventive medicine \[[@CIT0025]--[@CIT0032]\]. Within the HIV field, secondary prophylaxis against *Pneumocystis carinii* pneumonia with cotrimoxazole was introduced among PLH \[[@CIT0033]\]. After several evolving regimes, in 2013 WHO recommended that all women living with HIV found to be pregnant should start regular ART, whereas newborns should receive a six-week ARV course \[[@CIT0034]\]. Over time, PMTCT approaches and successes have played a key role in shaping the initial thinking about using PrEP to prevent sexually acquired HIV infections.

Early controversies around oral PrEP clinical trials {#S0002-S20002}
----------------------------------------------------

An overview of the complex history of ideas and research that contributed to the development of PrEP is relevant as it may, in part, explain some remaining controversies \[[@CIT0035]\]. After animal studies demonstrated the protective effects of pre-exposure ARV use and successful early phase human studies demonstrated safety \[[@CIT0036]--[@CIT0038]\], the planning of phase III trials to assess the efficacy of oral PrEP using tenofovir (tenofovir disoproxil fumarate (TDF), Viread^®^) generated interest among HIV prevention scientists, but also some concerns among other stakeholders. [Table 1](#T0001){ref-type="table"} shows a list of planned PrEP trials in 2004 and 2005, including four trials terminated before or after enrollment had started.

###### 

First generation of HIV pre-exposure prophylaxis trials

  Sponsor   Place, expected start date                  Population                   Exposure         Sample size   Study aim             Duration (months)   Status
  --------- ------------------------------------------- ---------------------------- ---------------- ------------- --------------------- ------------------- -----------------------------
  NIH/FHI   Cambodia, 2004                              Women                        Vaginal          960           Safety and efficacy   12                  Stopped before start
  FHI       Ghana, 2005                                 Women                        Vaginal          400           Safety                12                  Completed
  FHI       Nigeria, 2005                               Women                        Vaginal          400           Safety                12                  Stopped after enrolling 120
  FHI       Cameroon, 2005                              Women                        Vaginal          400           Safety                12                  Stopped after enrolling 400
  FHI       Malawi, 2005                                Heterosexual men             Penile           400           Safety                12                  Stopped before start
  CDC       Thailand, 2005                              PWID                         Parenteral       1200          Safety and efficacy   12                  Completed
  CDC       Botswana, 2005                              Heterosexual men and women   Vaginal/penile   1600          Safety and efficacy   18                  Completed
  CDC       San Francisco, Atlanta, Boston, USA; 2005   MSM                          Penile/rectal    400           Safety                15                  Completed
  NIH       Peru/Ecuador, 2007                          MSM                          Penile/rectal    1400          Safety and efficacy   18                  Completed

NIH, National Institutes of Health; FHI360, Family Health International; CDC, US Center for Disease Control, PWID, people who inject drugs; MSM, men who have sex with men.

Four trials planned for implementation in Cambodia, Cameroon, Nigeria, and Malawi were cancelled due to controversies. The Cambodia trial, focused on PrEP safety and efficacy among female sex workers, never started due to concerns that, if women became HIV-infected, they would not have access to lifelong treatment, while losing their source of livelihood \[[@CIT0035], [@CIT0039]--[@CIT0042]\]. In early 2005, similar studies in women at high HIV risk were cancelled in Cameroon (due to allegations of inappropriate standards \[[@CIT0043]\]) and Nigeria (where the sponsor considered that conditions for study conduct were inappropriate \[[@CIT0035], [@CIT0037], [@CIT0044]\]). In Malawi, the government stopped the trial due to fear of drug resistance developing if participants became infected during implementation \[[@CIT0044]\]. The trial planned among people who injected drugs (PWID) in Thailand risked cancellation due to stakeholders' allegations of unethical standards (i.e. not offering clean needles and syringes, in addition to methadone, according to WHO guidelines) \[[@CIT0045]\]. The trial finished in May 2011 \[[@CIT0012]\], but PWID organizations have reiterated that the trial was unethical and its conclusions are not acceptable \[[@CIT0046]\].

In May 2005, a stakeholder consultation was convened with the participation of trial funders and community representatives from Cameroon, Ghana, Malawi, and Thailand \[[@CIT0047]\]. Participants agreed that an immediate evaluation of trial design and protocol procedures was needed in ongoing and future trials to ensure compliance with the highest standards of care, civil society participation in trial design and conduct, and availability of mechanisms for feedback and conflict resolution at study sites \[[@CIT0044]\]. Addressing one of the recommendations, the Joint United Nations Programme on HIV/AIDS, in collaboration with Global Advocacy for HIV Prevention (AVAC), consulting with communities, revised and produced a series of guidelines \[[@CIT0048]--[@CIT0052]\] for ethical assessment and definition of appropriate standards of study conduct in international HIV research. It conveyed the message that the scientific community had addressed the concerns raised about the ongoing trials, and that, together with communities, a new framework of operation had been established.

Implementation of the major oral PrEP efficacy trials: mixed results and lessons learned {#S0002-S20003}
----------------------------------------------------------------------------------------

Increasing global access to ARTs and better-tolerated single and combined formulations, together with resolution of the initial controversies, eventually resulted in the implementation of PrEP trials. Some of the delayed PrEP trials, along with new ones, were rolled out between 2007 and 2013. Those trials included the following: two among women only (i.e. FEM-PrEP \[[@CIT0053]\] and VOICE \[[@CIT0054]\]), in addition to a vaginal gel study (CAPRISA 004 \[[@CIT0009]\]); two among heterosexuals (i.e. Partners PrEP in serodiscordant couples and TDF2 in heterosexuals at high risk \[[@CIT0012], [@CIT0055]\]); one among men who have sex with men (MSM) and transwomen (iPrEx) in the Americas, South Africa, and Thailand \[[@CIT0056]\]; and one among PWID (the CDC BTS) in Thailand \[[@CIT0013]\]. Given concerns for resistance based on results of a preclinical study in macaques \[[@CIT0057]\], the investigators of iPrEx and TDF2 decided to use, instead of tenofovir alone, the combination of tenofovir and emtricitabine (as offered in the formulation of Truvada^®^ by Gilead); while Partners PrEP opted to have separate arms for TDF and tenofovir - emtricitabine (TDF-FTC) for comparison. [Table 2](#T0002){ref-type="table"} shows the list of oral PrEP trials conducted, as well as their mixed results.

###### 

PrEP randomized controlled trials and their findings

  ------------------------------------------------------------------------------------------------------------------------------------------
  Study (reference)                      Location                                                       Population   Efficacy   
  -------------------------------------- -------------------------------------------------------------- ------------ ---------- ------------
  iPrEx (Grant *et al*. 2010)            Peru, Ecuador, Brazil, United States, South Africa, Thailand   MSM          42         18 to 60%

  Partners PrEP (Baeten *et al*. 2011)   Kenya, Uganda                                                  Men          84         49 to 94%

                                                                                                        Women        66         19 to 82%

  TDF2 (Thigpen *et al*. 2012)           Botswana                                                       Men          80         25 to 97%

                                                                                                        Women        49         22 to 81%

  FEM-PrEP (Van Damme *et al*. 2012)     Kenya, Tanzania                                                Women        6          −52 to 42%

  VOICE (Marazzo *et al*. 2013)          South Africa, Uganda\                                          Women        −4         −50 to 30%
                                         Zimbabwe                                                                               

  The CDC BTS (Choopaya *et al*. 2013)   Thailand                                                       PWID         49         10 to 72%

  Ipergay (Molina *et al*. 2015)         France, Canada                                                 MSM          86         39 to 98%

  PROUD (McCormack *et al*. 2015)        United Kingdom                                                 MSM          86         58 to 96%
  ------------------------------------------------------------------------------------------------------------------------------------------

The protective effects of the first three PrEP trials ([Table 2](#T0002){ref-type="table"}) completed in 2010 to 2011 (i.e. iPrEx, Partners PrEP, and TDF2) \[[@CIT0012], [@CIT0055]\] generated optimism. The subsequent termination of FEM-PrEP and VOICE due to futility \[[@CIT0053], [@CIT0054]\], however, led to assessments of the potential sources of such variability. Data on ARV concentration in serum, plasma, PBMCs, and hair showed highly variable adherence within and across sites, which likely explained important differences between intent-to-treat findings and those controlling for effective dose exposure. Overall adherence was extremely low in FEM-PrEP and VOICE, explaining their outcomes \[[@CIT0058]\], as there is no evidence of interference of oral contraceptives in the protective effect of oral PrEP. Retrospective analyses that used mathematical modelling on those data showed that efficacy was strongly associated with detectable drug in serum or tissues. High adherence was associated with over 99% protection in iPrEx \[[@CIT0059], [@CIT0060]\]. Importantly, these analyses also showed the presence of "forgiveness": oral PrEP is probably protective with less than daily dosing (although with no less than four doses per week), and such forgiveness may be lower in women due to relatively lower concentrations in vaginal tissue, compared to rectal tissue, after the same oral dose \[[@CIT0061]\].

Oral PrEP and effectiveness from subsequent studies {#S0002-S20004}
---------------------------------------------------

Low adherence levels in the efficacy trials raised concerns about the feasibility of PrEP as a public health strategy. Nevertheless it was recognized that real-life adherence to a product of demonstrated effectiveness would probably be different from adherence in a placebo-controlled trial, where participants are told that intervention efficacy is still unclear and that half of them are receiving a placebo \[[@CIT0062]\]. This effect was demonstrated by the open label extension of iPrEx \[[@CIT0063]\], where high levels of adherence were reported, and PrEP reduced incidence among those who consistently took the medication. Likewise, in October 2014, the UK PROUD study of immediate versus delayed PrEP for MSM accessing services at UK sexual health clinics stopped the deferred treatment arm and offered PrEP to all participants, given the protection demonstrated in their ongoing pilot study \[[@CIT0064]\]. Two weeks later, the French Ipergay trial of intermittent, pericoital PrEP terminated the placebo arm based on an interim analysis that showed adherence and "considerable efficacy" \[[@CIT0065]\]. In February 2015, findings from both studies showed similar (86%) effectiveness in preventing HIV infection among MSM at increased risk, who overall showed high adherence. The overall picture is that MSM who are motivated to use PrEP can achieve sufficient adherence to have even greater reduction in HIV as compared to iPrEx findings \[[@CIT0066]\].

In a different epidemic context (i.e. serodiscordant couples in generalized epidemic settings), the Partners Demonstration Project, an open label observational study of PrEP and early treatment in Kenya and Uganda, also showed an overall relative risk reduction of 96% in an interim analysis \[[@CIT0067]\]. These results suggest the use of PrEP as a bridge in serodiscordant couples -- whereby the HIV-negative partner takes PrEP for protection while waiting for the HIV-positive partner to start treatment and minimize viral load. Several demonstration projects are starting in other countries, many of which are focusing on female sex workers (FSWs), namely, in Benin, India, Kenya, Senegal, South Africa, and Zimbabwe. It is becoming clear that these demonstration projects will help design PrEP implementation plans as part of combination prevention in programmatic contexts.

The post-trial context of PrEP: effective need, programmatic dilemmas, and social paradoxes {#S0002-S20005}
-------------------------------------------------------------------------------------------

As of early mid-2015, evidence supporting PrEP effectiveness could justify more active scaling up. However, should PrEP ever become an important component of the global HIV response, several issues need to be tackled.

### Concerns prior to trial outcomes

Some early concerns have not been fully addressed or have adopted new dimensions. First, PrEP raised substantial resistance because it destabilized the social norm of "100% condom use," which prevented so many infections in three decades, while in fact that social norm had already started to recede \[[@CIT0068], [@CIT0069]\]. Second, PrEP was misunderstood as intended to replace condoms, while in fact it was meant to become one element (but never the sole element) of the emerging paradigm of combination prevention \[[@CIT0023]\]. Third, many objected to a perceived medicalization of HIV prevention, although this perception can be interpreted as fear of turning prevention into a mechanical process with no social-structural component; recent studies have shown that successful PrEP implementation retains the need for social interaction and the importance of community buy-in. Fourth, the controversies surrounding the early phases of the international PrEP trials led to fears that PrEP would be implemented in a compulsory way among key populations (e.g. sex workers) or serve as an excuse to not provide basic prevention tools (e.g. harm reduction for injection drug users), paying no attention to human rights \[[@CIT0070]--[@CIT0074]\]. From reactions so far, because PrEP is not cheap, its compulsory use seems unlikely with key populations anywhere. Fifth, PLH organizations and some policy makers have feared competition with treatment in an era of decreased resources, although it now seems clear that the PrEP component of HIV response, in order to remain cost-effective, should be focused on small fractions of the population at very high risk, while different strategies should be used with others \[[@CIT0071]\]. Finally, PrEP may have generated a "moral panic" in certain stakeholders concerned about a potential loss of sexual restraints, leading to so-called risk compensation (i.e. having riskier sex and thereby neutralizing the benefit of PrEP). Even within the gay community, this concern has created a certain stigma affecting PrEP \[[@CIT0075]\]. With the current media focus on PrEP and MSM, many assume that MSM should "be responsible and just use condoms," which provide sufficient protection to them. This view fails to take into account the following: 1) for many MSM, condoms are not a feasible option, for several reasons, including loss of pleasure and power dynamics in relationships \[[@CIT0076], [@CIT0077]\]; 2) a more nuanced discussion is missing about the potential benefits of PrEP for women, including female sex workers and transwomen, for whom PrEP offers a prevention strategy that is under their control \[[@CIT0078]--[@CIT0080]\].

### Public health and clinical guidance

In 2012, through its standard guideline development procedure, the WHO issued a conditional recommendation for PrEP use among serodiscordant couples and among men and transgender women who have sex with men, from a public health approach. It called for demonstration projects to assess conditions for potential PrEP implementation \[[@CIT0081]\]. In 2014, the WHO updated its guidance and released a strong recommendation for governments to consider adding PrEP components to their combination prevention strategies for MSM in countries with high disease burden in those populations \[[@CIT0023]\]. In the United States, a prophylactic indication for TDF-FTC for PrEP was approved in 2012 \[[@CIT0082]\], and in early 2014 the US Center for Disease Control consolidated the indication of PrEP for people at risk for HIV acquisition \[[@CIT0083]\].

Besides public health guidance (relevant for public prevention programmes set up by countries), clinical guidance is necessary where it is also recognized that PrEP is not meant to be used for life. As with any other prophylaxis, PrEP makes sense during periods of high exposure, which rarely cover an individual\'s entire life. Pericoital regimes, such as the focus of the Ipergay study \[[@CIT0084]\], may also play a role in transitioning out of PrEP. The context in which oral PrEP may be individually recommended to some people may present some commonalities with the context in which other drugs are currently used and recommended for the prevention of other diseases. For example, statins are used to prevent cardiovascular disease, as they are essentially safe, like ARV drugs, but can rarely cause serious toxicity \[[@CIT0085]\].

### Population focus

PrEP is recommended for those facing a genuinely high risk of acquiring HIV. Clearly the benefit to be obtained from PrEP depends on the incidence rate of HIV and this factor has to be balanced against the (small) risks of the medication. Although adverse events are infrequent among positives and negatives alike, the benefits of treatment for those living with HIV are very high, whereas the benefits of PrEP to those who are HIV-negative depend entirely on their chance of acquiring infection. Based on available incidence estimations and behavioural data, PrEP use could have a clear positive impact among MSM almost everywhere, among sex workers in many places, among young people in southern Africa, but also among serodiscordant couples and those trying to conceive, and other key populations in various settings (e.g. partners of migrant labourers or truck drivers) \[[@CIT0023]\]. Sound programmatic targeting is crucial to avoid PrEP ending up being prescribed mostly to the "worried well" \[[@CIT0086]\]. Concerns remain as to how to target persons who would benefit from PrEP in generalized epidemics (potentially based on geographies with the highest incidence).

*Access* is determined by specific prevention guidance from normative bodies, drug availability, and a financing regime (e.g. out of pocket, insurance, public health programme). Concerns have been raised about the control that the pharmaceutical industry might have over the prices of PrEP regimes -- which, at least in higher income countries, could be difficult to sustain \[[@CIT0087]--[@CIT0090]\]. Not without challenges, PrEP is slowly starting to be prescribed to at-risk Americans financed by medical insurance companies, national public health programmes for the poor or disabled, or through the producer of TDF-FTC, Gilead, via a drug assistance programme for underinsured individuals \[[@CIT0091]\]. Some programmes are making PrEP a part of combination prevention, such as New York City\'s MSM programme \[[@CIT0092]\] or the DREAMS initiative recently announced by U.S. President\'s Emergency Plan for AIDS Relief (PEPFAR) for 10 priority countries to provide a package of interventions aimed at tackling HIV among adolescent girls and young women \[[@CIT0093]\].

Recent developments in European Union PrEP trials may accelerate regulatory changes there, too. However, TDF-FTC is not only not licensed for use as a preventive measure elsewhere, it is not even available for treatment in a few countries. In many countries, drugs can be used "off-label," but usually only for acute indications with uncertain diagnosis or for life-threatening situations with no effective standard treatment, which would not be the case for PrEP. Nonetheless, demonstration projects ongoing in Brazil, several African countries, Thailand, and Australia, may lead to local approvals of TDF-FTC use for this indication. Finally, pricing is tied up with commercial decisions based on market estimations and trade agreements and also expressed in drug packaging and marketing.

### The role of condoms

Given concerns about so-called risk compensation, normative bodies have decided to continue to maintain that PrEP should be used together with condoms \[[@CIT0023], [@CIT0083], [@CIT0094]\]. However, initial data from demonstration studies in MSM show that people who choose to take PrEP may, in fact, be those who report episodes of unprotected anal intercourse, and their reported PrEP adherence is already high, with no subsequent risk compensation or change from their present condom use \[[@CIT0095]\]. Hence, at least among MSM, PrEP may become a choice among people at risk due to condomless anal sex, who feel that a daily pill may suit them better than condoms. Perhaps a compromise in PrEP messaging could include stating the following: 1) PrEP does not intend to replace condoms but to add to condom protection; 2) PrEP does not protect against bacterial STIs; 3) PrEP can become especially useful for those who have difficulties with consistent condom use, as long as it is taken as prescribed.

### Delivery

A few delivery models for local adaptation should be coming out soon from ongoing demonstration projects. It is likely, however, that some people who could benefit most from PrEP are those who find it most difficult to come routinely to a health service. Delivery models should be developed that are appropriate for the populations being served, while simultaneously being "fit for purpose" (e.g. they need to be integrated into the more holistic healthcare needs of the population, able to provide reliable HIV testing services, linked to HIV treatment services, able to detect serious toxicity, and able to refer complex or worrying cases into the broader health system) \[[@CIT0096], [@CIT0097]\]. Demonstration projects are evaluating delivery models. For example, PROUD delivered PrEP through sexual health clinics with quarterly visits in the United Kingdom \[[@CIT0084], [@CIT0098]\], whereas demonstration projects among sex workers in Benin and in South Africa are setting models where PrEP might work as part of a combination prevention package of PrEP and treatment as prevention (TasP). In India, PrEP is being evaluated to determine whether it can be implemented among brothel-based and street-based sex workers' health services; and in Zimbabwe it is being offered in the context of highway-based sex work. US demonstration projects are evaluating customized prevention packages for MSM and transwomen (TW), for example, some that may include PrEP, the "testing and linking" of young MSM of colour to sexual health services, and text-messaging intervention to improve adherence.

### Adherence, resistance to ARV and secondary effects

Practitioners feared that adherence in real life would be low (as in various trials), leading to resistance to a complex drug inappropriately used in primary care \[[@CIT0099], [@CIT0100]\]. Nevertheless, open label studies have shown that, among people who perceive its need, adherence can be very high \[[@CIT0101]\]. Adherence must be a central message to users, despite the forgiveness shown by studies so far \[[@CIT0059]\], where participants generally adhered well \[[@CIT0063]\]. Because PrEP is given to HIV-uninfected people, it cannot cause resistance unless the person first acquires HIV and then continues to take PrEP. That is why it is essential to build delivery systems that reliably check the HIV status of those wanting to take or continue to take PrEP and that avoid informal distribution channels. Mathematical models show that most resistance comes from PLH who are not fully adherent to treatment; hence, preventing new infections through the use of PrEP could reduce rather than exacerbate levels of resistance in a community. Finally, stakeholders also feared drug toxicities and secondary effects \[[@CIT0102], [@CIT0103]\], but the experience so far has shown that they remain at reasonably low levels \[[@CIT0104]--[@CIT0107]\].

Conclusions: perspectives and challenges in 2015 and beyond {#S0003}
===========================================================

A number of studies in the pipeline may streamline ARV-based prevention options even further, including the Ipergay trial (pericoital oral PrEP among MSM; this trial recently dropped the placebo arm \[[@CIT0065]\]); the Ring Study and ASPIRE (designed to determine whether a monthly vaginal ring that delivers dapivirine helps prevent HIV infection in women and is safe for long-term use) \[[@CIT0108], [@CIT0109]\]; and studies of ARVs with long half-lives, such as rilpivirine and cabotegravir, to be administered parenterally every eight to twelve weeks \[[@CIT0110], [@CIT0111]\]. Such approaches to PrEP delivery may eventually become more widely applicable than oral PrEP, but it will be several years before they are manufactured, licensed, available, and affordable.

Although individual oral PrEP prescription may become the only form of PrEP available in many places, governments may implement population-focused PrEP programmes for cost-effectiveness, considering costs, affordability, and financing. However, decisions on focused PrEP programmes for populations with uncontrolled ongoing HIV transmission should preferably be based on impact. Given the high price of Truvada^TM^ in high income countries, PrEP programmatic feasibility will in part be defined by the pharmaceutical industry\'s role in providing access to supplies of TDF or TDF-FTC globally in the near future. The ongoing licensing and pricing of TDF-FTC in many places will be challenging, particularly in the context of new free-trade agreements \[[@CIT0112]\]. Resolving current problems in treatment distribution in many countries and committing to ensuring its supply alongside the start of PrEP programmes will be central \[[@CIT0113]\].

In HIV epidemics concentrated on MSM, self-selection of high-risk men insufficiently protected by condoms, with higher adherence to PrEP and no evidence of risk compensation, as observed in demonstration projects, suggests a desirable fit between a new tool and a population in need. However, it also demonstrates the importance of interdisciplinary studies and critical policy analysis to better understand how PrEP is actually adopted by at-risk communities and, under those conditions, to understand the following: what factors could improve or affect its effectiveness; how different forms of PrEP delivery would avert new infections and what the cost-effectiveness ratio would be; what role mathematical modelling could play in effectiveness and cost-effectiveness analysis; and how policy dialogue could be promoted to ensure that this strategy is considered fairly by governments.

In conclusion, over the years, important research findings have improved our understanding of biomedical and social determinants of HIV transmission. These findings have provided the evidence needed to transform the preventive response with the inclusion of "highly active" prevention approaches, as well as social and structural strategies at various levels, in what is now called a "combination prevention framework." Among those prevention approaches, oral PrEP using TDF or TDF-FTC has emerged as an evidence-based option for people at risk of acquiring HIV. Despite its substantial potential, appropriate contribution of PrEP to the HIV response implies tackling two kinds of challenges: first, to clarify the numerous misconceptions that have led many to ignore the growing evidence of PrEP\'s utility; second, to fill research gaps concerning PrEP and its implementation and to resolve a number of issues related to its pertinence in different geographic and epidemiological contexts, health system structures and procedures, access, cost, and appropriate prioritization strategies. These are major challenges, proportional to the magnitude of the change we are witnessing in the dominant HIV prevention paradigm, one in which the impact of PrEP may finally help solidify the foundation of the so-far elusive concept of combination HIV prevention.
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